Clinical meaningfulness of complete skin clearance in psoriasis

Journal of the American Academy of Dermatology

Volumn 75, Issue 1, 2016, Pages 77-82.e7

  Strober, Bruce ^a   Papp, Kim A ^b,c   Lebwohl, Mark ^d   Reich, Kristian ^e   Paul, Carle ^f   Blauvelt, Andrew ^g   Gordon, Kenneth B ^h   Milmont, Cassandra E ⁱ   Viswanathan, Hema N ⁱ   Li, Joanne ⁱ   Pinto, Lionel ⁱ   Harrison, David J ⁱ   Kricorian, Greg ⁱ   Nirula, Ajay ⁱ   Klekotka, Paul ⁱ  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c K Papp Clinical Research   (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Dermatologikum Hamburg   (Germany)

^f UNIVERSITÉ PAUL SABATIER   (France)

^g OREGON MEDICAL RESEARCH CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

Dermatology Life Quality Index; health related quality of life; patient reported outcomes; plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; static Physician Global Assessment

Indexed keywords

BRODALUMAB;

ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE CLEARANCE; HUMAN; MINIMAL RESIDUAL DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; COMPLICATION; ERYTHEMA; FEMALE; MALE; MIDDLE AGED; PRURITUS; PSORIASIS; PSYCHOLOGY; REMISSION; SEVERITY OF ILLNESS INDEX;

ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; ERYTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PRURITUS; PSORIASIS; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84971333765     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.03.026     Document Type: Article

References (17)

1. S.K. Kurd, A.B. Troxel, P. Crits-Christoph, and J.M. Gelfand The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study Arch Dermatol 146 2010 891 895
2. S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer Jr., and D.M. Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407
3. H.L. Richards, D.G. Fortune, C.E. Griffiths, and C.J. Main The contribution of perceptions of stigmatization to disability in patients with psoriasis J Psychosom Res 50 2001 11 15
4. F. Sampogna, S. Tabolli, B. Soderfeldt, and et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36 Br J Dermatol 154 2006 844 849
5. H. Yeung, J. Takeshita, N.N. Mehta, and et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study JAMA Dermatol 149 2013 1173 1179
6. Y. Hongbo, C.L. Thomas, M.A. Harrison, M.S. Salek, and A.Y. Finlay Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 125 2005 659 664
7. D.A. Revicki, M.K. Willian, A. Menter, J.H. Saurat, N. Harnam, and M. Kaul Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis Dermatology 216 2008 260 270
8. R. Shikiar, B.W. Bresnahan, S.P. Stone, C. Thompson, J. Koo, and D.A. Revicki Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials Health Qual Life Outcomes 1 2003 53
9. R. Shikiar, M.K. Willian, M.M. Okun, C.S. Thompson, and D.A. Revicki The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study Health Qual Life Outcomes 4 2006 71
10. C.E.M. Griffiths, K. Reich, M. Lebwohl, and et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials Lancet 386 2015 541 551
11. R.G. Langley, B.E. Elewski, M. Lebwohl, and et al. Secukinumab in plaque psoriasis-results of two phase 3 trials N Engl J Med 371 2014 326 338
12. M. Lebwohl, B. Strober, A. Menter, and et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis N Engl J Med 373 2015 1318 1328
13. T. Fredriksson, and U. Pettersson Severe psoriasis-oral therapy with a new retinoid Dermatologica 157 1978 238 244
14. S.R. Feldman, and G.G. Krueger Psoriasis assessment tools in clinical trials Ann Rheum Dis 64 Suppl 2 2005 ii65 ii73
15. A.Y. Finlay, and G.K. Khan Dermatology Life Quality Index (DLQI)- A simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
16. J. Takeshita, K. Callis Duffin, D.B. Shin, and et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting J Am Acad Dermatol 71 2014 633 641
17. H.N. Viswanathan, D. Chau, C.E. Milmont, and et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis J Dermatolog Treat 26 3 2015 235 239